LEUKEMIAS

Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.

Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.

Findings suggest that combination regimens may extend overall and progression-free survival.

In an interview with Targeted Oncology, Haris Ali, MD, a hematology oncologist at the City of Hope Cancer Center, discussed the efficacy of ruxolitinib in patients with myelofibrosis, the impact of mutations on ruxolitinib treatment, and the use of the agent in the peri-transplant setting.

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

The use of zanubrutinib was found to be noninferior to treatment with ibrutinib for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, meeting the primary end point of the phase 3 ALPINE trial.

The FDA has granted priority review to the sterile injectable therapy SH-111 for the treatment of pediatric patients with T-cell leukemia.

In the phase 1/2 AUGMENT-101 clinical trial, treatment with the novel menin-MLL small molecule inhibitor SNDX-5613 led to robust clinical responses in patients with mixed lineage leukemia rearranged and NPM1c-mutant relapsed or refractory acute leukemias.

In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discusses the chance of cardiovascular toxicities with BTK inhibitors and the safety of acalabrutinib.

The FDA has granted an orphan drug designation to CA-4948, a first-in-class, small-molecule inhibitor of IRAK4, for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the impact of ruxolitinib on MF and other issues facing the patient population. 

GTB-3550 TriKE had demonstrated early clinical promise as a monotherapy for the treatment of high-risk myelodysplastic syndromes and refractory/relapsed acute myeloid leukemia.

A supplemental biologics license application for brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory B-cell precursors acute lymphoblastic leukemia.

Blinatumomab consolidation demonstrated significantly prolonged event-free survival in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia when compared with chemotherapy before allogeneic hematopoietic stem cell transplantation.

Usama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each

Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.

The FDA granted Breakthrough Therapy Designation to the novel STAMP inhibitor asciminib for 2 populations of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.

During a Targeted Oncology Case-Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed therapeutic options for a 71-year-old patients with chronic lymphocytic leukemia and a genomic aberration.

The FDA has approved ponatinib for the treatment of adult patients with chronic-phase chronic myeloid leukemia with resistance or intolerance of at least 2 prior tyrosine kinase inhibitors.

Treatment with asciminib led to an almost doubling of the major molecular response rate compared with bosutinib at 24 weeks in patients with chronic-phase chronic myeloid leukemia.

High response rates and robust survival outcomes among patients with chronic-phase chronic myeloid leukemia who failed prior treatment with a second-generation tyrosine kinase inhibitor were observed in 2 clinical trials of ponatinib,.

Adult patients with acute lymphoblastic leukemia who have relapsed following hematopoietic cell transplantation have experienced considerably improved survival benefits over the past few years, which may be due to an increased use of immunotherapy.

A real-world analysis showed the positive safety and efficacy of the investigational tyrosine kinase inhibitor asciminib as treatment of patients with chronic myeloid leukemia without any alternatives in clinical practice.

Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

During a debate, Nicholas J. Short, MD, argued that intensive chemotherapy combined with a BCR-ABL tyrosine kinase inhibitor still holds the place of standard-of-care treatment for Phildelphia chromosome acute lymphoblastic leukemia, while Sabina Chiaretti, MD, PhD, made the case for targeted therapy.

There are several indications for the use of allo-SCT in adults. With the implementation of targeted therapies, these are continuously changing.